Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.
Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.
Richard Bloch, advocate for patient information services, dead at 78.
STAR completes enrollment.
NCI forms pediatric central IRB.
Funding opportunities listed.
July issue of Business & Regulatory report (8 additional pages) included.
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - ACOG says it will no longer accept federal funding
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025 - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
